바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
사전등록 바로가기
 

Tuberculosis & Respiratory Diseases

논문 상세

이전
논문 투고

Vol.74 No.1
Citation Share

Erlotinib Induced Trichomegaly of the Eyelashes

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2013, v.74 no.1, pp.37-40
전상훈 (인하대학교)
유정선 (인하대학교)
최광성 (인하대학교)
김정수 (인하대학교의과대학부속병원)
권혜윤 (인하대학교)
김민수 (인하대학교)
남해성 (인하대학교)
조재화 (인하대학교)
곽승민 (인하대학교)
이홍렬 (인하대학교)
김현정 (인하대학교)
홍근정 (인하대학교)
전상훈, 유정선, 최광성, 김정수, 권혜윤, 김민수, 남해성, 조재화, 곽승민, 이홍렬, 김현정, & 홍근정. (2013). . Tuberculosis & Respiratory Diseases, 74(1), 37-40.
  • 다운로드 수
  • 조회수
PDF 다운로드

Abstract

Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many patients treated with EGFR TKIs. However trichomegaly of eyelash is rarely reported. Although trichomegaly is not a drug-limiting side effect, it could be troublesome of continuing the treatment because of cosmetic issue or eyeball irritation by long eyelashes. Therefore clinicians are needed to pay attention to this uncommon effect. We herein describe erlotinib induced trichomegaly of eyelashes in a woman with adenocarcinoma of the lung.

keywords
Receptor, Epidermal Growth Factor, Erlotinib, Lung Neoplasms, Eyelashes, Physiological Effects of Drugs

참고문헌

1.

Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.

2.

Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22: 3238-47.

3.

Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol 2006;1:1040-1.

4.

Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23:65-6.

5.

Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004;151:1111-2.

6.

Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-74.

7.

Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-2.

8.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

9.

Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1711-2.

10.

Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.

11.

Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from nonsmall cell lung cancer. J Thorac Oncol 2009;4:684-8.

Tuberculosis & Respiratory Diseases

논문 투고 OA 정책